Fetal safety of macrolides

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3307-3311

  Dinur, Anat Bahat ^a,f   Koren, Gideon ^e,f   Matok, Ilan ^e,f   Wiznitzer, Arnon ^a,c   Uziel, Elia ^b,c   Gorodischer, Rafael ^a,c,d,f   Levy, Amalia ^f,g  

^a Department of Public Health ^*  (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d CLALIT HEALTH SERVICES   (Israel)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f BeMORE Collaboration (Ben Gurion Motherisk Obstetric Registry of Exposure Collaboration)   (Israel)

^g BeMORE Collaboration (Ben Gurion Motherisk Obstetric Registry of Exposure Collaboration)   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; ROXITHROMYCIN;

APGAR SCORE; ARTICLE; CARDIOVASCULAR MALFORMATION; CONGENITAL MALFORMATION; DATA BASE; DIABETES MELLITUS; DRUG EXPOSURE; DRUG SAFETY; ETHNICITY; FETOTOXICITY; FIRST TRIMESTER PREGNANCY; HOSPITALIZATION; HUMAN; INDUCED ABORTION; INTUSSUSCEPTION; ISRAEL; LIVE BIRTH; LOW BIRTH WEIGHT; MATERNAL AGE; MATERNAL DIABETES MELLITUS; MEDICAL RECORD; PERINATAL MORTALITY; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; PYLORUS STENOSIS; REGISTER; SIDE EFFECT; THIRD TRIMESTER PREGNANCY; TREATMENT DURATION;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CARDIOVASCULAR ABNORMALITIES; COHORT STUDIES; FEMALE; HUMANS; INFANT, NEWBORN; INTUSSUSCEPTION; ISRAEL; MACROLIDES; MIDDLE AGED; PERINATAL MORTALITY; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PYLORIC STENOSIS; REGISTRIES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84879019058     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01691-12     Document Type: Article

References (33)

1. Katzung BG, Masters SB, Trevor AJ. 2009. Basic and clinical pharmacology, 11th ed. p 799-801. McGraw-Hill, New York, NY.
2. Chambers HF. 2011. Protein synthesis inhibitors and miscellaneous antibacterial agents, p 1521-1547. In Brunton LL, Chabner BA, Knollmann BC (ed). Goodman & Gilman's the pharmacological basis of therapeutics, 12th ed. McGraw Hill, New York, NY.
3. Jain R, Danziger LH. 2004. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview current pharmaceutical design. Curr. Pharm. Des. 10:3045-3053. (Pubitemid 39242900)
4. Bush MR, Rosa C. 1994. Azithromycin and erythromycin in the treatment of cervical chlamydial infection during pregnancy. Obstet. Gynecol. 84:61-63. (Pubitemid 24202958)
5. Adair CD, Gunter M, Stovall TG, McElroy G, Veille JC, Ernest JM. 1998. Chlamydia in pregnancy: a randomized trial of azithromycin and erythromycin. Obstet. Gynecol. 91:165-168. (Pubitemid 28074141)
6. Ogasawara K, Goodwin M. 1999. Efficacy of Azithromycin in reducing lower genital ureaplasma urealyticum colonization in women at risk for preterm delivery. J. Matern. Fetal Med. 8:12-16. (Pubitemid 29070268)
7. Kenyon S, Boulvain M, Neilson JP. 2009. Antibiotics for preterm rupture of membranes. The Cochrane Collaboration. John Wiley & Sons, Ltd., New York, NY.
8. Edwards M, Rainwater K, Carter S. 1994. Comparison of azithromycin and erythromycin, for Chlamydia cervicitis in pregnancy. Am. J. Obstet. Gynecol. 170:419.
9. Heikkinen T, Laine K, Neuvonen PJ, Ekblad U. 2000. The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. Br. J. Obstet. Gynaecol. 107:770-775. (Pubitemid 30311914)
10. Ramsey PS, Vaules MB, Vasdev GM. 2003. Maternal and transplacental pharmacokinetics of azithromycin. Am. J. Obstet. Gynecol. 188: 714-718. (Pubitemid 36332439)
11. Briggs GG, Freeman RK, Yaffe SJ. 2011. Drugs in pregnancy and lactation: a reference guide to fetal and neonate risk, 9th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
12. Heinonen OP, Slone D, Shapiro S. 1977. Birth defects and drugs in pregnancy. Publishing Science Group, Littleton, MA.
13. Romoren M, Lindbaek M. 2012. Pregnancy outcome after gestational exposure to erythromycin-a population based register study from Norway. Br. J. Clin. Pharmacol. 74:1053-1062.
14. Källén B, Olausson P. 2003. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod. Toxicol. 17:255-261. (Pubitemid 36626946)
15. Bar-Oz B, Diav-Citrin O, Shechtman S. 2008. Pregnancy outcome after gestational exposure to the new macrolides: a prospective multicenter observational study. Eur. J. Obstet. Gynecol. Reprod. Biol. 141: 31-34.
16. Bar-Oz B, Weber-Schoendorfer C. 2012. The outcomes of pregnancy in women exposed to the new macrolides in the first trimester. Drug Saf. 35:589-598.
17. Sarkar M, Woodland C, Koren G. 2006. Pregnancy outcome following gestational exposure to azithromycin. BMC Pregnancy Childbirth 6:18.
18. Chun JY, Han JY, Ahn HK. 2006. Fetal outcome following roxithromycin exposure in early pregnancy. J. Matern. Fetal Neonatal. Med. 19:189-192.
19. Einarson A, Phillip E, Mawji F, D'Alimonte D, et al. 1998. A prospective controlled multicentre study of clarithromycin in pregnancy. Am. J. Perinatol. 15:523-525. (Pubitemid 29017981)
20. Drinkard CR, Shatin D, Clouse J. 2000. Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations. Pharmacoepidemiol. Drug Saf. 9:549-556. (Pubitemid 32294102)
21. Cooper WO, Griffin MR, Arbogast P. 2002. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch. Pediatr. Adolesc. Med. 156:647-650. (Pubitemid 34755991)
22. Hauben M, Amsden G. 2002. The association of erythromycin and infantile hypertrophic pyloric stenosis, causal or coincidental? Drug Safety 25:929-942. (Pubitemid 35252718)
23. Hviid A, Svanström H. 2009. Antibiotic use and intussusception in early childhood. J. Antimicrob. Chemother. 64:642-648.
24. Levy A, Matok I, Gorodischer R, Sherf M, Wiznitzer A, Uziel E, Koren G. 2012. Bias toward the null hypothesis in pregnancy drug studies that do not include data on medical terminations of pregnancy: the folic acid antagonists. J. Clin. Pharmacol. 52:78-83.
25. The Israeli Central Bureau of Statistics (CBS). 2013. Statistical abstracts of Israel 2008. No. 59. Population by district, subdistrict and religion. http://ww w.cbs.gov.il/reader/shnaton/templ-shnaton-e.html?num-tab- st02-06x&C Year-2008. Accessed 7 April 2013.
26. The Israeli Central Bureau of Statistics (CBS). 2013. Patterns of fertility in 2006. http://www.cbs.gov.il/hodaot2007n/01-07-215b.pdf. Accessed 7 April 2013.
27. The Israeli Central Bureau of Statistics (CBS). 2013. Local authorities by socio-economic index value, rank and cluster membership http://www.cbs.gov. il/hodaot2013n/24-13-087-local-autorities-a2.xls. Accessed 7 April 2013.
28. WHO Collaborating Centre for Drug Statistics Methodology. 2012. ATC/DDD index 2013. http://www.whocc.no/atcddd/. Accessed 15 February 2012.
29. Centers for Disease Control and Prevention. 2011. Metropolitan Atlanta Congenital Defects Program. http://www.cdc.gov/ncbddd/bd/macdp.htm. Accessed 6 June 2011.
30. Correa-Villasenor A, Cragan J, Kucik J, O'Leary L, Siffel C, Williams L. 2003. The Metropolitan Atlanta Congenital Defects Program: 35 years of birth defects surveillance at the Centers for Disease Control and Prevention. Birth Defects Res. A Clin. Mol. Teratol. 67:617-624. (Pubitemid 37222110)
31. Rasmussen SA, Olney RS, Holmes LB, Lin AE, Keppler-Noreuil KM, Moore CA. 2003. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res. A Clin. Mol. Teratol. 67:193-201. (Pubitemid 37238061)
32. Matok I, Gorodischer R, Koren G, Eyal Sheiner E, Wiznitzer A, Levy A. 2009. The safety of metoclopramide use in the first trimester of pregnancy. N. Engl. J. Med. 360:2528-2535.
33. Koren G, Pastuszak AP, Ito S. 1998. Drugs in pregnancy. N. Engl. J. Med. 338:1128-1137. (Pubitemid 28227484)